SMT201700121T1 - Sale amorfo di un inibitore macrociclico di hcv - Google Patents

Sale amorfo di un inibitore macrociclico di hcv

Info

Publication number: SMT201700121T1
Authority: SM; San Marino
Prior art keywords: hcv; amorphous salt; macrocyclic inhibitor; macrocyclic; inhibitor
Prior art date: 2009-02-27

Application number

SM20170121T

Other languages

English (en)

Inventor

Remoortere Peter Jozef Maria Van

Roger Petrus Gerebern Vandecruys

Kock Herman De

Original Assignee

Janssen Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-27

Filing date

2010-02-26

Publication date

2017-03-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201700121(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-26 Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc

2017-03-08 Publication of SMT201700121T1 publication Critical patent/SMT201700121T1/it

Links

239000003112 inhibitor Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

SM20170121T 2009-02-27 2010-02-26 Sale amorfo di un inibitore macrociclico di hcv SMT201700121T1 (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09153964		2009-02-27
EP10706539.3A EP2401272B1 (en)	2009-02-27	2010-02-26	Amorphous salt of a macrocyclic inhibitor of hcv
PCT/EP2010/001197 WO2010097229A2 (en)	2009-02-27	2010-02-26	Amorphous salt of a macrocyclic inhibitor of hcv

Publications (1)

Publication Number	Publication Date
SMT201700121T1 true SMT201700121T1 (it)	2017-03-08

Family

ID=40756982

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SM20170121T SMT201700121T1 (it)	2009-02-27	2010-02-26	Sale amorfo di un inibitore macrociclico di hcv
SM201700121T SMT201700121B (it)	2009-02-27	2017-02-22	Sale amorfo di un inibitore macrociclico di hcv

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SM201700121T SMT201700121B (it)	2009-02-27	2017-02-22	Sale amorfo di un inibitore macrociclico di hcv

Country Status (26)

Country	Link
US (2)	US9321758B2 (it)
EP (2)	EP3150596A1 (it)
JP (2)	JP5711672B2 (it)
KR (2)	KR101868412B1 (it)
CN (2)	CN102356080B (it)
AU (1)	AU2010219160B2 (it)
BR (1)	BRPI1008918A2 (it)
CA (2)	CA2898529C (it)
CY (1)	CY1119121T1 (it)
DK (1)	DK2401272T3 (it)
ES (1)	ES2616603T3 (it)
HK (1)	HK1208464A1 (it)
HR (1)	HRP20170214T1 (it)
HU (1)	HUE031738T2 (it)
IL (2)	IL214398A0 (it)
LT (1)	LT2401272T (it)
MX (1)	MX340792B (it)
NZ (1)	NZ594403A (it)
PL (1)	PL2401272T3 (it)
PT (1)	PT2401272T (it)
RU (1)	RU2536868C2 (it)
SG (2)	SG173772A1 (it)
SI (1)	SI2401272T1 (it)
SM (2)	SMT201700121T1 (it)
WO (1)	WO2010097229A2 (it)
ZA (1)	ZA201106303B (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI454476B (zh)	2008-07-08	2014-10-01	Tibotec Pharm Ltd	用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
SMT201700121T1 (it) *	2009-02-27	2017-03-08	Janssen Pharmaceuticals Inc	Sale amorfo di un inibitore macrociclico di hcv
JP5781706B2 (ja) *	2011-12-29	2015-09-24	アッヴィ・アイルランド・アンリミテッド・カンパニー	Ｈｃｖ阻害剤を含む固体組成物
US9034832B2 (en) *	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
JP2015526504A (ja) *	2012-08-31	2015-09-10	ヤンセンファーマシューティカルズ，インコーポレーテッド	Ｈｃｖの大環状プロテアーゼ阻害剤と、非ヌクレオシドｈｃｖ阻害剤と、リトナビルとの組み合わせ
EP2950786B1 (en)	2013-01-31	2019-11-27	Gilead Pharmasset LLC	Combination formulation of two antiviral compounds
AU2014233705C1 (en) *	2013-03-15	2019-10-10	Boehringer Ingelheim International Gmbh	Solid oral dosage formulation of HCV inhibitor in the amorphous state
EA201690473A1 (ru)	2013-08-27	2017-03-31	ГАЙЛИД ФАРМАССЕТ ЭлЭлСи	Комбинированный состав двух противовирусных соединений
CN104995189B (zh) *	2014-01-21	2017-03-29	杭州普晒医药科技有限公司	丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105308043B (zh) *	2014-05-29	2018-01-30	杭州普晒医药科技有限公司	丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2016054240A1 (en) *	2014-09-30	2016-04-07	Sean Dalziel	Fixed dose combinations for the treatment of viral diseases
CZ2015220A3 (cs) *	2015-03-27	2016-10-05	Zentiva, K.S.	Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en)	2015-05-04	2016-11-10	Sandoz Ag	Amorphous simeprevir potassium
WO2017017604A1 (en)	2015-07-27	2017-02-02	Lupin Limited	Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060083784A1 (en) *	2002-08-07	2006-04-20	Smithkline Beecham Corporation	Amorphous pharmaceutical compositions
CN1889970B (zh) *	2003-10-14	2012-06-13	F·霍夫曼-罗须公司	作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
ES2336009T3 (es)	2004-01-30	2010-04-07	Medivir Ab	Inhibidores de la ns-3 serina proteasa del vhc.
EP1720884A1 (de) *	2004-02-24	2006-11-15	Siegfried Generics International AG	Pharmakologisch akzeptierbare salze von clopidogrel
UA91677C2 (ru) *	2004-03-30	2010-08-25	Интермюн, Инк.	Макроциклические соединения как ингибиторы вирусной репликации
EP1749007A2 (en)	2004-03-30	2007-02-07	Intermune, Inc.	Macrocyclic compounds as inhibitors of viral replication
WO2006054317A1 (en) *	2004-11-19	2006-05-26	Matrix Laboratories Ltd	Process for the preparation of novel amorphous montelukast sodium
PE20070343A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Inhibidores macrociclicos del virus de la hepatitis c
PE20070211A1 (es) *	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP2008115173A (ja) *	2006-10-13	2008-05-22	Eisai R & D Management Co Ltd	スルフィニルベンズイミダゾール化合物の塩およびそれらの結晶ならびに非晶質体
WO2008073195A2 (en)	2006-11-08	2008-06-19	Duke University	Method for activation of oxazaphosphorines
RU2483067C2 (ru) *	2007-02-01	2013-05-27	Тиботек Фармасьютикалз Лтд.	Способы и промежуточные продукты для получения макроциклического ингибитора протеазы вируса гепатита с
SI2118098T1 (sl) *	2007-02-01	2015-01-30	Janssen R&D Ireland	Polimorfne oblike makrocikličnega inhibitorja HCV
EP2185516A2 (en)	2007-08-29	2010-05-19	Pfizer Products Incorporated	Polymorphs of 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof and methods for making the same
SMT201700121T1 (it) *	2009-02-27	2017-03-08	Janssen Pharmaceuticals Inc	Sale amorfo di un inibitore macrociclico di hcv

2010
- 2010-02-26 SM SM20170121T patent/SMT201700121T1/it unknown
- 2010-02-26 WO PCT/EP2010/001197 patent/WO2010097229A2/en not_active Ceased
- 2010-02-26 DK DK10706539.3T patent/DK2401272T3/en active
- 2010-02-26 SG SG2011059862A patent/SG173772A1/en unknown
- 2010-02-26 NZ NZ594403A patent/NZ594403A/xx not_active IP Right Cessation
- 2010-02-26 RU RU2011139325/04A patent/RU2536868C2/ru not_active IP Right Cessation
- 2010-02-26 KR KR1020177005726A patent/KR101868412B1/ko not_active Expired - Fee Related
- 2010-02-26 MX MX2011008999A patent/MX340792B/es active IP Right Grant
- 2010-02-26 PT PT107065393T patent/PT2401272T/pt unknown
- 2010-02-26 HU HUE10706539A patent/HUE031738T2/en unknown
- 2010-02-26 SI SI201031402A patent/SI2401272T1/sl unknown
- 2010-02-26 CN CN201080009908.9A patent/CN102356080B/zh not_active Expired - Fee Related
- 2010-02-26 JP JP2011551440A patent/JP5711672B2/ja not_active Expired - Fee Related
- 2010-02-26 PL PL10706539T patent/PL2401272T3/pl unknown
- 2010-02-26 CN CN201410616884.3A patent/CN104478868A/zh active Pending
- 2010-02-26 KR KR1020117022464A patent/KR101713066B1/ko not_active Expired - Fee Related
- 2010-02-26 CA CA2898529A patent/CA2898529C/en not_active Expired - Fee Related
- 2010-02-26 BR BRPI1008918A patent/BRPI1008918A2/pt not_active Application Discontinuation
- 2010-02-26 CA CA2753667A patent/CA2753667C/en not_active Expired - Fee Related
- 2010-02-26 ES ES10706539.3T patent/ES2616603T3/es active Active
- 2010-02-26 EP EP16195560.4A patent/EP3150596A1/en not_active Withdrawn
- 2010-02-26 EP EP10706539.3A patent/EP2401272B1/en active Active
- 2010-02-26 US US13/202,166 patent/US9321758B2/en not_active Expired - Fee Related
- 2010-02-26 AU AU2010219160A patent/AU2010219160B2/en not_active Ceased
- 2010-02-26 SG SG2014008981A patent/SG2014008981A/en unknown
- 2010-02-26 HR HRP20170214TT patent/HRP20170214T1/hr unknown
- 2010-02-26 LT LTEP10706539.3T patent/LT2401272T/lt unknown
2011
- 2011-08-02 IL IL214398A patent/IL214398A0/en unknown
- 2011-08-26 ZA ZA2011/06303A patent/ZA201106303B/en unknown
2015
- 2015-03-06 JP JP2015044264A patent/JP6214584B2/ja not_active Expired - Fee Related
- 2015-09-21 HK HK15109245.7A patent/HK1208464A1/xx unknown
- 2015-12-22 IL IL243058A patent/IL243058A0/en unknown
2016
- 2016-03-08 US US15/063,821 patent/US20160251345A1/en not_active Abandoned
2017
- 2017-02-22 SM SM201700121T patent/SMT201700121B/it unknown
- 2017-02-22 CY CY20171100246T patent/CY1119121T1/el unknown

Also Published As

Publication number	Publication date
MX340792B (es)	2016-07-25
CY1119121T1 (el)	2018-02-14
CA2753667C (en)	2015-11-17
HUE031738T2 (en)	2017-07-28
HRP20170214T1 (hr)	2017-04-07
US20160251345A1 (en)	2016-09-01
CN102356080B (zh)	2015-04-29
EP2401272A2 (en)	2012-01-04
BRPI1008918A2 (pt)	2016-03-15
MX2011008999A (es)	2011-09-26
JP5711672B2 (ja)	2015-05-07
NZ594403A (en)	2013-07-26
HK1208464A1 (en)	2016-03-04
RU2536868C2 (ru)	2014-12-27
JP2015143240A (ja)	2015-08-06
CA2898529C (en)	2017-10-17
SMT201700121B (it)	2017-03-08
WO2010097229A3 (en)	2010-11-11
HK1166315A1 (en)	2012-10-26
PT2401272T (pt)	2017-02-28
SI2401272T1 (sl)	2017-04-26
KR20170026660A (ko)	2017-03-08
CA2898529A1 (en)	2010-09-02
CN104478868A (zh)	2015-04-01
KR101868412B1 (ko)	2018-06-18
EP3150596A1 (en)	2017-04-05
JP2012519158A (ja)	2012-08-23
AU2010219160A1 (en)	2011-08-25
SG2014008981A (en)	2014-04-28
KR101713066B1 (ko)	2017-03-07
DK2401272T3 (en)	2017-02-27
IL214398A0 (en)	2011-09-27
LT2401272T (lt)	2017-03-27
ZA201106303B (en)	2013-02-27
US20110306634A1 (en)	2011-12-15
KR20110123273A (ko)	2011-11-14
ES2616603T3 (es)	2017-06-13
US9321758B2 (en)	2016-04-26
CA2753667A1 (en)	2010-09-02
JP6214584B2 (ja)	2017-10-18
IL243058A0 (en)	2016-02-29
AU2010219160B2 (en)	2015-12-10
CN102356080A (zh)	2012-02-15
WO2010097229A2 (en)	2010-09-02
PL2401272T3 (pl)	2017-06-30
SG173772A1 (en)	2011-09-29
EP2401272B1 (en)	2017-01-11
RU2011139325A (ru)	2013-04-10

Publication	Publication Date	Title
IL243058A0 (en)	2016-02-29	Amorphous salt of macrocyclic hcv inhibitor
HUS000511I2 (hu)	2021-03-29	Gilteritinib vagy sója
EP2410841A4 (en)	2012-10-24	SUBSTITUTED BICYCLIC HCV INHIBITORS
IL216648A0 (en)	2012-03-01	Crystalline forms of febuxostat
AP3079A (en)	2015-01-31	A slush
IL221198A0 (en)	2012-10-31	Crystalline salts of a potent hcv inhibitor
PT2611779T (pt)	2016-11-21	Formas cristalinas de um inibidor do fator xa
SG10201408584UA (en)	2015-02-27	Crystalline Methylthionium Chloride Hydrates
IL215315A0 (en)	2011-12-29	Solid state forms of sitagliptin salts
AP3169A (en)	2015-03-31	A method of improved positioning
EP2504343A4 (en)	2013-04-17	HEPATITIS C INHIBITOR COMPOUNDS
PL2301943T3 (pl)	2014-06-30	Krystalizacja epidaunorubicyny x HCI
PL2333462T3 (pl)	2017-06-30	Trzy postacie lodu z pojedynczego wgłębienia
AP2013006733A0 (en)	2013-02-28	Solid state forms of a potent HCV inhibitor
IL220307A (en)	2015-04-30	Secondary history of 8-hydroxyquinoline-7-carboxamide
GB2458027B (en)	2010-01-20	A method of selection
GB0904499D0 (en)	2009-04-29	A set of parts
GB0903651D0 (en)	2009-04-15	Inhibitors of glyoxalase
GB0919237D0 (en)	2009-12-16	Improvements of a device
GB0902782D0 (en)	2009-04-08	Disposal of metal salts
SI2398784T1 (sl)	2013-02-28	Kristalna oblika febuksostata
PH32009000313S1 (en)	2009-11-16	Portion of a toothbrush
PH32009000714S1 (en)	2010-07-19	Portion of a toothbrush
PH32009000317S1 (en)	2009-11-16	Portion of a toothbrush
PH32009000713S1 (en)	2010-08-23	Portion of a toothbrush